Erleada® (Apalutamide) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Overall Survival Compared to Enzalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer
Erleada®（阿帕魯胺）在轉移性去勢敏感型前列腺癌患者中顯示出與嗎替韋相比在總生存期上有統計學意義且臨床意義明顯的改善